A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice

Vaccine

Volumn 22, Issue 9-10, 2004, Pages 1162-1171

  Mazumdar, Tuhina ^a,b   Anam, Khairul ^a,c   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Liposomes; Vaccination; Visceral leishmaniasis

Indexed keywords

CHOLESTEROL; DRUG CARRIER; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; LEISHMANIA VACCINE; LIPOSOME; PARASITE ANTIGEN; PHOSPHATIDYLCHOLINE; STEARIC ACID DERIVATIVE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOWN REGULATION; DRUG FORMULATION; ENCAPSULATION; HEPATOSPLENOMEGALY; INFECTION RESISTANCE; INFECTION SENSITIVITY; LEISHMANIA DONOVANI; LIVER PROTECTION; MACROPHAGE ACTIVATION; MITOGENESIS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SPLEEN; SPLEEN CELL; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL DIVISION; CYTOKINES; DRUG CARRIERS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; LIVER; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PROTOZOAN VACCINES; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 1542330963     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.030     Document Type: Article

References (61)

1. Pearson RD, Souza AQ, Jeronimo, SMB. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practise of infectious diseases V. Philadelphia: Churchill Livingstone; 2000; p. 2831-44.
2. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14(2):2001;229-243.
3. Alvar J., Canavate C., Gutierrez-Solar B.et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10(2):1997;298-319.
4. Lockwood D.N.J. Commentary: some good news for treatment of visceral leishmaniasis in Bihar. Brit. Med. J. 316(7139):1998;1205.
5. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health. 6(11):2001;849-854.
6. Badaro R., Jones T.C., Carvalho E.M.et al. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154(6):1986;1003- 1011.
7. Haldar J.P., Ghose S., Saha K.C., Ghose A.C. Cell mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis. Infect. Immun. 42(2):1983;702-707.
8. Reed S.G., Campos-Neto A. Vaccines for parasitic and bacterial diseases. Curr. Opin. Immunol. 15:2003;1-5.
9. Daneshvar H., Combs G.H., Hagan P., Phillips R.S. Leishmania mexicana and Leishmania major: attenuation of wild type parasites and vaccination with attenuated lines. J. Infect. Dis. 187(10):2003;1662-1668.
10. Follador I., Araujo C., Orge G.et al. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony stimulating factors. Vaccine. 20(9-10):2002;1365- 1368.
11. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146(8):1991;2763-2770.
12. Holbrook T.W., Cook J.A. Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes. Am. J. Trop. Med. Hyg. 32(1):1983;51-53.
13. Jarecki-Black J.C., Glassman A.B., James E.R. Adoptive transfer of vaccine-induced resistance to Leishmania donovani. Am. J. Trop. Med. Hyg. 34(6):1985;1095-1097.
14. Jaffe C.L., Rachamim N., Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J. Immunol. 144(2):1990;699-706.
15. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice from both cutaneous and visceral leishmaniasis. J. Immunol. 150(6):1993;2322-2331.
16. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36 (LACK) DNA is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69(8):2001;4719-4725.
17. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., Palatnik de Sousa C.B. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine. 19(9-10):2000;1082-1092.
18. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O.et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine. 20(27-28):2002;3277-3284.
19. Louis J., Himmelrich H., Parra-Lopez C., Tacchini-Cottier F., Launois P. Regulation of protective immunity against Leishmania major in mice. Curr. Opin. Immunol. 10(4):1998;459-464.
20. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62(3):1994;1058-1063.
21. Carvalho E.M., Badaro R., Reed S.G., Jones T.C., Johnson W.D. Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76(6):1985;2066-2069.
22. Murray H.W., Squires K.E., Miralles C.D.et al. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J. Immunol. 148(6):1992;1858-1863.
23. Alving C.R., Wassef N.M. Cytotoxic T lymphocytes induced by liposomal antigens:mechanism of immunological presentation. AIDS Res. Hum. Retrovirus. 10:1994;S91-S94.
24. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 16(7):1998;307-321.
25. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today. 11:1990;89-97.
26. Ambrosch F., Wiedermann G., Jonas S.et al. Immunogenecity and protectivity of a new liposomal hepatitis A vaccine. Vaccine. 15(11):1997;1209-1219.
27. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., Alving C.R. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen. Infect. Immun. 66(6):1998;2859-2865.
28. Fernandes I., Frisch B., Muller S., Schuber F. Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen. Mol. Immunol. 34(8-9):1997;569-976.
29. Gregoriadis G. Liposome technology, vol. I, 2nd ed. Boca Raton, FL: CRC Press; 1993.
30. Brewer J.M., Tetley L., Richmond J., Liew F.Y., Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161(8):1998;4000-4007.
31. Nakanishi T., Kunisawa J., Hayashi A.et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble protein. J. Control Release. 61(1-2):1999;233-240.
32. Frezard F. Liposomes from biophysics to the design of peptide vaccines. Braz. J. Med. Biol. Res. 32(2):1999;181-189.
33. + T-cell responses in vivo. Blood. 96(10):2000;3505-3513.
34. Afrin F., Rajesh R., Anam K., Gopinath M., Pal S., Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun. 70(12):2002;6697-6706.
35. Bakouche O., Gerlier D. Enhancement of immunogenecity of tumour virus antigen by liposomes: the effect of lipid composition. Immunology. 58(3):1986;507-513.
36. Gregoriadis G., Panagiotidi C. Immunoadjuvant action of liposomes: comparison with other adjuvants. Immunol. Lett. 20(3):1989;237-240.
37. Kahl L.P., Scott C.A., Lelchuk R., Gregoriadis G., Liew F.Y. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. J. Immunol. 142(12):1989;4441-4449.
38. Afrin F., Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 65(6):1997;2371-2377.
39. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193(1):1951;265-276.
40. Stauber L.A., Franchino E.M., Grun J. An 8-day method for screening compounds against Leishmania donovani in the golden hamster. J. Protozool. 5(4):1958;269-273.
41. Afrin F., Dey T., Anam K., Ali N. Leishmanicidal activity of stearylamine-bearing liposomes in vitro. J. Parasitol. 87(1):2001;188-193.
42. Satoskar A.R., Roding S., Tedford S.R. IL-12 gene deficient C57B2/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur. J. Immunol. 30(3):2000;834-839.
43. Ding A.H., Nathan C.F., Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141(7):1988;2407-2412.
44. Afrin F., Ali N. Isotype profiles of Leishmania donovani infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens. J. Parasitol. 84(4):1998;743-748.
45. Ali N., Afrin F. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J. Parasitol. 83(1):1997;70-75.
46. Stager S., Smith D.F., Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165(12):2000;7064-7071.
47. Melby P.C., Yang Y.-Z., Cheng J., Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66(1):1998;18-27.
48. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177(5):1998;1352-1357.
49. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263(5144):1994;235-237.
50. Sjölander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis. J. Immunol. 16(20):1998;2077-2084.
51. Murray H.W. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 175(6):1997;1477-1479.
52. Squires K.E., Schreiber R.D., McElrath M.J., Rubin B.Y., Anderson S.L., Murray H.W. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 143(12):1989;4244-4249.
53. Taylor A.P., Murray H.W. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene disrupted mice. J. Exp. Med. 185(7):1997;1231-1239.
54. Murray H.W., Nathan C.F. Macrophage microbicidal mechanisims in vivo: reactive nitrogen versus oxygen intermediates in killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189(4):1999;741-746.
55. Gicheru M.M., Olobo J.O., Anjili C.O., Orago A.S., Modabber F., Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun. 69(1):2001;245-251.
56. Sjölander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine. 16(20):1998;2077-2084.
57. Satoskar A., Bluethmann H., Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63(12):1995;4894-4899.
58. Streit J.A., Recker T.J., Filho F.G., Beverley S.M., Wilson M.E. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical infection with virulent but not avirulent organisms. J. Immunol. 166(3):2001;1921-1929.
59. Ghosh A., Zhang W.W., Matlashewski G. Immunization with A2 protein results in mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infection. Vaccine. 20(1-2):2001;59-66.
60. Bullens D.M.A., Kasran A., Thielemans K., Bakkus M., Ceuppens J.L. CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand. J. Immunol. 53(5):2001;455-463.
61. Biedermann T., Zimmermann S., Himmerlrich H.et al. IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nature Immunol. 2(11):2001;1054-1060.